Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
Scope of the Report:
This report studies the Factor VIII Deficiency Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Factor VIII Deficiency Treatment market by product type and applications/end industries.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
The global Factor VIII Deficiency Treatment market is valued at xx million in 2017 and is expected to reach xx million by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Factor VIII Deficiency Treatment.
Europe also play important roles in global market, with market size of xx million in 2017 and will be xx million in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Shire
Bayer HealthCare
CSL
Grifols
Novo Nordisk
F. Hoffmann-La Roche
Kedrion
Octapharma
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
Market Segment by Applications, can be divided into
Hospitals
Clinics
Other
Frequently Asked Questions
Table Of Content
Table of Contents
1 Factor VIII Deficiency Treatment Market Overview
1.1 Product Overview and Scope of Factor VIII Deficiency Treatment
1.2 Classification of Factor VIII Deficiency Treatment by Types
1.2.1 Global Factor VIII Deficiency Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Factor VIII Deficiency Treatment Revenue Market Share by Types in 2017
1.2.3 Hemophilia A Drugs
1.2.4 Hemophilia A Inhibitors Treatment
1.2.5 Von Willebrand Disease Treatment
1.3 Global Factor VIII Deficiency Treatment Market by Application
1.3.1 Global Factor VIII Deficiency Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Factor VIII Deficiency Treatment Market by Regions
1.4.1 Global Factor VIII Deficiency Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Factor VIII Deficiency Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Factor VIII Deficiency Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Factor VIII Deficiency Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Factor VIII Deficiency Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Factor VIII Deficiency Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Factor VIII Deficiency Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Factor VIII Deficiency Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Shire
2.2.1 Business Overview
2.2.2 Factor VIII Deficiency Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Shire Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer HealthCare
2.3.1 Business Overview
2.3.2 Factor VIII Deficiency Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer HealthCare Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 CSL
2.4.1 Business Overview
2.4.2 Factor VIII Deficiency Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 CSL Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Grifols
2.5.1 Business Overview
2.5.2 Factor VIII Deficiency Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Grifols Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Novo Nordisk
2.6.1 Business Overview
2.6.2 Factor VIII Deficiency Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Novo Nordisk Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 F. Hoffmann-La Roche
2.7.1 Business Overview
2.7.2 Factor VIII Deficiency Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 Kedrion
2.8.1 Business Overview
2.8.2 Factor VIII Deficiency Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Kedrion Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Octapharma
2.9.1 Business Overview
2.9.2 Factor VIII Deficiency Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Octapharma Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 Biogen Idec
2.10.1 Business Overview
2.10.2 Factor VIII Deficiency Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Biogen Idec Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.11 BioMarin Pharmaceutical
2.11.1 Business Overview
2.11.2 Factor VIII Deficiency Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.12 Sangamo Therapeutics
2.12.1 Business Overview
2.12.2 Factor VIII Deficiency Treatment Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.13 Spark Therapeutics
2.13.1 Business Overview
2.13.2 Factor VIII Deficiency Treatment Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Spark Therapeutics Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.14 Swedish Orphan Biovitrum
2.14.1 Business Overview
2.14.2 Factor VIII Deficiency Treatment Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.15 Uniqure NV
2.15.1 Business Overview
2.15.2 Factor VIII Deficiency Treatment Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Uniqure NV Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.16 Amarna Therapeutics
2.16.1 Business Overview
2.16.2 Factor VIII Deficiency Treatment Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Amarna Therapeutics Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.17 Dimension Therapeutics
2.17.1 Business Overview
2.17.2 Factor VIII Deficiency Treatment Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Dimension Therapeutics Factor VIII Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Factor VIII Deficiency Treatment Market Competition, by Players
3.1 Global Factor VIII Deficiency Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Factor VIII Deficiency Treatment Players Market Share
3.2.2 Top 10 Factor VIII Deficiency Treatment Players Market Share
3.3 Market Competition Trend
4 Global Factor VIII Deficiency Treatment Market Size by Regions
4.1 Global Factor VIII Deficiency Treatment Revenue and Market Share by Regions
4.2 North America Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
5 North America Factor VIII Deficiency Treatment Revenue by Countries
5.1 North America Factor VIII Deficiency Treatment Revenue by Countries (2013-2018)
5.2 USA Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
6 Europe Factor VIII Deficiency Treatment Revenue by Countries
6.1 Europe Factor VIII Deficiency Treatment Revenue by Countries (2013-2018)
6.2 Germany Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.4 France Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Factor VIII Deficiency Treatment Revenue by Countries
7.1 Asia-Pacific Factor VIII Deficiency Treatment Revenue by Countries (2013-2018)
7.2 China Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.5 India Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
8 South America Factor VIII Deficiency Treatment Revenue by Countries
8.1 South America Factor VIII Deficiency Treatment Revenue by Countries (2013-2018)
8.2 Brazil Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Factor VIII Deficiency Treatment by Countries
9.1 Middle East and Africa Factor VIII Deficiency Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Factor VIII Deficiency Treatment Revenue and Growth Rate (2013-2018)
10 Global Factor VIII Deficiency Treatment Market Segment by Type
10.1 Global Factor VIII Deficiency Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Factor VIII Deficiency Treatment Market Forecast by Type (2018-2023)
10.3 Hemophilia A Drugs Revenue Growth Rate (2013-2023)
10.4 Hemophilia A Inhibitors Treatment Revenue Growth Rate (2013-2023)
10.5 Von Willebrand Disease Treatment Revenue Growth Rate (2013-2023)
11 Global Factor VIII Deficiency Treatment Market Segment by Application
11.1 Global Factor VIII Deficiency Treatment Revenue Market Share by Application (2013-2018)
11.2 Factor VIII Deficiency Treatment Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Other Revenue Growth (2013-2018)
12 Global Factor VIII Deficiency Treatment Market Size Forecast (2018-2023)
12.1 Global Factor VIII Deficiency Treatment Market Size Forecast (2018-2023)
12.2 Global Factor VIII Deficiency Treatment Market Forecast by Regions (2018-2023)
12.3 North America Factor VIII Deficiency Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Factor VIII Deficiency Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Factor VIII Deficiency Treatment Revenue Market Forecast (2018-2023)
12.6 South America Factor VIII Deficiency Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Factor VIII Deficiency Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Inquiry For Buying
Factor VIII Deficiency Treatment
Request Sample
Factor VIII Deficiency Treatment
